Daruvir (darunavir) and with other antiretroviral agents, are indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor. This indication is based on analyses of plasma HIV RNA levels and CD4 cell counts from controlled Phase 3 trials of 48 weeks duration in antiretroviral treatment-experienced patients and controlled Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients.